|Slideshows|March 10, 2022

The Impact of Daylight Savings Time

Author(s)Danielle Penney, BSc, Colin M. Shapiro, PhD, MBBCh, FRCPC

What do you and your patients need to know about adjusting to daylight savings time?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

ByAshley A. Mulvihill, MD ,Susan Hatters Friedman, MD, MSt, DFAPA

July 17th 2026

Podcast: Managing Co-Occurring Mood and Substance Use Disorders With Michael J. Ostacher, MD, MPH

ByJoseph F. Goldberg, MD,Michael J. Ostacher, MD, MPH

July 17th 2026

What's Next for Psychedelics in Psychiatry? COMP360 and Beyond

ByGustavo Alva, MD, DFAPA,Jessica Walters

July 16th 2026

Vagus Nerve Stimulation in Difficult-to-Treat Depression: When Does It Work Best?

ByGustavo Alva, MD, DFAPA

July 14th 2026

COMP360 Psilocybin in Treatment-Resistant Depression: Insights From Gus Alva, MD, DFAPA

ByGustavo Alva, MD, DFAPA

July 11th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

The Impact of Daylight Savings Time

Related Content

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

Podcast: Managing Co-Occurring Mood and Substance Use Disorders With Michael J. Ostacher, MD, MPH

What's Next for Psychedelics in Psychiatry? COMP360 and Beyond

Vagus Nerve Stimulation in Difficult-to-Treat Depression: When Does It Work Best?

COMP360 Psilocybin in Treatment-Resistant Depression: Insights From Gus Alva, MD, DFAPA

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease

New Ingrezza Data Shows Improved Quality of Life and Daily Functioning in Tardive Dyskinesia

Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety